カテゴリ： GlobalData, スウェーデン, 企業調査

Karolinska Development AB (KDEV)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Karolinska Development AB (KDEV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8066
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：67
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スウェーデン
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Karolinska Development AB (Karolinska Development) is a life sciences investment company that develops innovations from science into commercial products. The company invests in start up’s and growth of the pharmaceutical, medical device and biotechnology companies that develop specialty care products and orphan drugs for patients suffering from life-threatening diseases in the areas of oncology, infections and wound healing, inflammation, cardiovascular disease, and women’s health. Its portfolio icompanies include Aprea Therapeutics AB, Dilafor AB, Forendo Pharma Oy, OssDsign AB, Modus Therapeutics AB, and others. It serves researchers, patients, and investors. Karolinska Development is headquartered in Solna, Sweden.

Karolinska Development AB (KDEV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karolinska Development AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karolinska Development AB, Medical Devices Deals, 2012 to YTD 2018 10
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karolinska Development AB, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Umecrine Cognition Raises USD2.5 Million in Venture Financing 14
Umecrine Cognition Raises USD4.8 Million in Venture Financing 15
Dilafor Raises USD6 Million in Venture Financing 16
Aprea Therapeutics Raises USD52 Million in Series B Financing 17
Umecrine Cognition Raises Funds in Private Financing Round 18
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 19
Forendo Pharma Raises Funds In First Round Of Venture Financing 21
GliGene Raises US$1 Million In First Round Of Financing 22
ProNoxis Raises US$0.6 Million In Venture Financing 23
Equity Offering 24
Pharmanest to Raise Funds through Private Placement of Shares 24
Xspray Pharma Raises USD1.3 Million in IPO 25
Modus Therapeutics Raises USD3.6 Million in Financing 26
Karolinska Development Raises USD8.5 Million in Private Placement of Series B Shares 27
Acquisition 28
Karolinska Development Divests its Remaining Stake in BioArctic for USD1.4 Million 28
Karolinska Development Divests its Stake in Lipidor 29
Karolinska Development Divests Certain Stake in BioArctic for USD4 Million 30
Karolinska Development Sells its Stake in Xspray Pharma for USD1.6 Million 31
KDev Investments Sells Stake in Inhalation Sciences 32
Ostersjostiftelsen Consortium to Acquire Stake in Athera Biotechnologies from Karolinska Development 33
Ostersjostiftelsen and Recipharm Venture Acquire Stake in XSpray Microparticles 35
Ostersjostiftelsen, Recipharm Venture and Praktikerinvest Acquire Stake in Pharmanest from Karolinska Development 36
Ostersjostiftelsen Acquires Stake in Axelar from Karolinska Development 37
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 38
Redoxis Acquires Remaining 54% Stake In ProNoxis From Karolinska And LU Bio 41
Karolinska Development AB – Key Competitors 42
Karolinska Development AB – Key Employees 43
Karolinska Development AB – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 44
Recent Developments 45
Financial Announcements 45
Aug 16, 2018: Karolinska Development: Interim Report January – June 2018 45
Apr 25, 2018: Karolinska Development: Interim Report January – March 2018 47
Feb 15, 2018: Karolinska Development: Q4 and 2017 Year-End Report – January-December 48
Oct 31, 2017: Karolinska Development Publishes Interim Report (January – September 2017) And Reports A Positive Result For The Third Quarter 50
Aug 29, 2017: Karolinska Development: Interim Report – January-June 2017 51
May 16, 2017: Karolinska Development: Interim Report – January-March 2017 52
Feb 28, 2017: Karolinska Development Q4 net loss decreases 53
Corporate Communications 54
May 21, 2018: Pharmanest Appoints Helena Jansson As Chief Executive Officer 54
Mar 15, 2018: Karolinska Development’s portfolio company Modus Therapeutics appoints a new Chief Medical Officer 55
Dec 29, 2017: Karolinska Development’s Chairman of the Board resigns from his position 56
Oct 31, 2017: Changes in the Board of Directors at Karolinska Development 57
Oct 12, 2017: First day of trading in Karolinska Development’s portfolio company BioArctic’s shares on Nasdaq Stockholm 58
Sep 14, 2017: Karolinska Developments’s portfolio company Modus Therapeutics recruits new Chief Medical Officer 59
Sep 13, 2017: Karolinska Development’s Portfolio Company BioArctic Intends to list on Nasdaq Stockholm 60
Aug 29, 2017: Karolinska Development Appoints Fredrik Jarrsten as Chief Financial Officer 61
Aug 25, 2017: Karolinska Development Notes the Planned Listing of Xspray on Nasdaq First North 62
Apr 24, 2017: Karolinska Development company Modus Therapeutics announces appointment of Ellen K. Donnelly, Ph.D. as CEO 63
Apr 20, 2017: Karolinska Development announces Chairman Bo Jesper Hansen and CEO Jim Van heusden’s decision to Step Down, and the promotion of Viktor Drvota to CEO 64
Apr 20, 2017: Karolinska Development announces board changes 65
Mar 01, 2017: Karolinska Development names deputy CEO 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
Karolinska Development AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karolinska Development AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karolinska Development AB, Deals By Therapy Area, 2012 to YTD 2018 9
Karolinska Development AB, Medical Devices Deals, 2012 to YTD 2018 10
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Umecrine Cognition Raises USD2.5 Million in Venture Financing 14
Umecrine Cognition Raises USD4.8 Million in Venture Financing 15
Dilafor Raises USD6 Million in Venture Financing 16
Aprea Therapeutics Raises USD52 Million in Series B Financing 17
Umecrine Cognition Raises Funds in Private Financing Round 18
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 19
Forendo Pharma Raises Funds In First Round Of Venture Financing 21
GliGene Raises US$1 Million In First Round Of Financing 22
ProNoxis Raises US$0.6 Million In Venture Financing 23
Pharmanest to Raise Funds through Private Placement of Shares 24
Xspray Pharma Raises USD1.3 Million in IPO 25
Modus Therapeutics Raises USD3.6 Million in Financing 26
Karolinska Development Raises USD8.5 Million in Private Placement of Series B Shares 27
Karolinska Development Divests its Remaining Stake in BioArctic for USD1.4 Million 28
Karolinska Development Divests its Stake in Lipidor 29
Karolinska Development Divests Certain Stake in BioArctic for USD4 Million 30
Karolinska Development Sells its Stake in Xspray Pharma for USD1.6 Million 31
KDev Investments Sells Stake in Inhalation Sciences 32
Ostersjostiftelsen Consortium to Acquire Stake in Athera Biotechnologies from Karolinska Development 33
Ostersjostiftelsen and Recipharm Venture Acquire Stake in XSpray Microparticles 35
Ostersjostiftelsen, Recipharm Venture and Praktikerinvest Acquire Stake in Pharmanest from Karolinska Development 36
Ostersjostiftelsen Acquires Stake in Axelar from Karolinska Development 37
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 38
Redoxis Acquires Remaining 54% Stake In ProNoxis From Karolinska And LU Bio 41
Karolinska Development AB, Key Competitors 42
Karolinska Development AB, Key Employees 43
Karolinska Development AB, Subsidiaries 44
Karolinska Development AB, Joint Venture 44

List of Figures
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karolinska Development AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Karolinska Development AB (KDEV)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Centrex Metals Ltd：企業の戦略・SWOT・財務分析
    Centrex Metals Ltd - Strategy, SWOT and Corporate Finance Report Summary Centrex Metals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Odonate Therapeutics LLC-製薬・医療分野：企業M&A・提携分析
    Summary Odonate Therapeutics LLC (Odonate) is a company that develops medicines for the treatment of cancer. It develops best in class medicines that enhance and extend the lives of patients suffering from cancer. Odonate’s lead product candidate, tesetaxel, is a novel orally administered taxane use …
  • Teva Pharmaceutical Industries Limited：企業の戦略・SWOT・財務情報
    Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • H&E Equipment Services Inc (HEES)：企業の財務・戦略的SWOT分析
    Summary H&E Equipment Services Inc (H&E Equipment) is an integrated equipment company that provides rentals and sales services. The company rents, sells and provides parts and service support for new and used earthmoving equipments, material handling, forestry, concrete, industrial and heavy equipme …
  • Avenue Supermarts Limited (DMART)：企業の財務・戦略的SWOT分析
    Avenue Supermarts Limited (DMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Lees Foods Ltd.：企業の戦略・SWOT・財務分析
    Lees Foods Ltd. - Strategy, SWOT and Corporate Finance Report Summary Lees Foods Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Murata Manufacturing Co Ltd (6981)：企業の財務・戦略的SWOT分析
    Murata Manufacturing Co Ltd (6981) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Visaka Industries Ltd：企業の戦略・SWOT・財務情報
    Visaka Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Visaka Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fauji Fertilizer Bin Qasim Ltd (FFBL)：企業の財務・戦略的SWOT分析
    Fauji Fertilizer Bin Qasim Ltd (FFBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Esperion Therapeutics Inc (ESPR)：製薬・医療：M&Aディール及び事業提携情報
    Summary Esperion Therapeutics Inc (Esperion), a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprote …
  • Bloomsbury Publishing Plc (BMY)：企業の財務・戦略的SWOT分析
    Bloomsbury Publishing Plc (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Pfizer Inc (PFE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, …
  • InterContinental Hotels Group Plc：企業の戦略・SWOT・財務情報
    InterContinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report Summary InterContinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Philippine National Bank
    Philippine National Bank - Strategy, SWOT and Corporate Finance Report Summary Philippine National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Premaitha Health Plc (NIPT)：企業の財務・戦略的SWOT分析
    Premaitha Health Plc (NIPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Selective Insurance Group, Inc. (SIGI)：企業の財務・戦略的SWOT分析
    Selective Insurance Group, Inc. (SIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • H.I.S. Co Ltd：企業の戦略・SWOT・財務分析
    H.I.S. Co Ltd - Strategy, SWOT and Corporate Finance Report Summary H.I.S. Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • DURECT Corp (DRRX)-医療機器分野：企業M&A・提携分析
    Summary DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s …
  • Telephonics Corporation：企業の戦略的SWOT分析
    Telephonics Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Orkla ASA：企業のM&A・事業提携・投資動向
    Orkla ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Orkla ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆